Ted Gastineau is the President and co-founder of ICON Medical Imaging (Beacon Bioscience).a leading specialist CRO in the medical imaging field. In 2004, ICON acquired a 70% interest in Beacon, and acquired the remaining 30% in 2010.
Prior to Beacon, Ted co-founded Intelligent Imaging, a research company specializing in imaging, which was acquired by Quintiles in 1997. From 1997-2000 he served as Senior Vice-President and Business Unit Head within Quintiles. Ted has more than 20 years in imaging for drug development and has worked closely with industry, FDA, and academia to establish best practices in place today.
Ted has held academic positions with the University of Maryland, Johns Hopkins School of Medicine, Cambridge University and the Smithsonian Institution. He holds a bachelors degree in Zoology and pursued a PhD in neurophysiology prior to founding Intelligent Imaging.
Richard Gastineau is an ICON Medical Imaging co-founder and serves as General Counsel for the division. Mr. Gastineau is an attorney and entrepreneur with over ten years of healthcare related experience. He co-founded Intelligent Imaging, Inc., a multinational pharmaceutical research firm and formerly served as its COO and General Counsel.
Mr. Gastineau acted as lead counsel and negotiated the sale of Intelligent Imaging, Inc. to Quintiles Inc. in August 1997. He served as Vice President, Operations, Quintiles, Inc. from 1997 through 2000 with global responsibility for strategic development, finance and operations. He is a founding partner of Valley Road Ventures, LLC, a business incubator and management consulting company. He has founded and successfully operated several businesses in the healthcare industry.
He has significant experience with venture funding and corporate finance, mergers and acquisitions, strategic planning and corporate development, joint ventures and strategic alliances, corporate operations and associated legal and financial matters including contract design and negotiation, intellectual property issues, employment issues, employment law matters and tax and financial management.
Mr. Gastineau currently serves on the Boards of Clinical Health Partners, Appalachian Medical Research and Valley Road Ventures. He also serves on the board of the Technology Resource Alliance, an entrepreneurial technology-focused consortium in the Philadelphia area.
He is a graduate of the University of North Carolina and earned his JD from Ohio Northern University School of Law and his LLM in taxation from the Georgetown University School of Law.
Andrew is the Executive Vice President of ICON Medical Imaging, and serves on its Board of Directors as one of its owners. In 2001, Andrew's Imaging CRO company BioCor, which he co-founded in 1998, was acquired by Beacon Bioscience. Prior to BioCor, Andrew was Senior Manager of Medical Imaging Systems at Bracco Diagnostics.
In his 18+ years of medical imaging in clinical research, Andrew has participated in numerous FDA-Sponsor meetings, and has installed imaging e-submissions at the FDA. He has converged his knowledge of clinical research, regulatory guidelines, study design and bioinformatics to produce industry leading solutions for the management, analysis and integrated review of medical images, clinical data, and study documents.
Andrew received his Bachelors and Masters degrees in Bioengineering from the University of Pennsylvania.
In her role as Senior Vice President, Clinical Operations at ICON Medical Imaging, Ms. Scanlan is responsible for a central and comprehensive facet of the specialty CRO services. As the keystone between clients, investigators, CROs and third-party vendors, her department is the face of ICON Medical Imaging. Under Ms. Scanlan’s leadership the department fulfills project management across a range of studies including cardiac, contrast agents, CNS, oncology, medical devices, rheumatology and other research (Phases I to IV).
With extensive industry and clinical imaging experience, Ms. Scanlan brings a wealth of expertise to imaging clinical trials; although her experience encompasses a range of therapeutic areas, Ms. Scanlan has advanced experience in oncology, particularly neuro-oncology, breast, prostate and gastric cancers, with a key area of interest in non-Hodgkin’s lymphoma.
Dr. Conklin is the Senior Vice President for Medical & Scientific Affairs at ICON Medical Imaging. Dr. Conklin is a Johns Hopkins trained research physician who is board certified in internal medicine and nuclear medicine.
He is a serial entrepreneur, who pioneered commercial imaging core laboratories as the founder, CEO and Chairman of Bio-Imaging Technologies; Inc, which he founded in 1990. He has also been CEO of pharmaceutical LIMS and EDC software companies. Before founding Bio-Imaging, Dr. Conklin was Vice President of Product Development at Cytogen Corporation, held a senior position at Centocor, Inc and was the Director of the Armed Forces Radiobiology Research Institute (AFRRI) the largest radiobiology research institute in the world with nearly 500 people. While at AFRRI, his laboratory was involved in discovering and developing biological response modifiers to treat various diseases using imaging technologies as a tool to measure treatment effectiveness. He was a member of an advisory team to the US Joint Chiefs of Staff, and the Department of Defense representative to the radiation science panel of the White House Office of the President Science and Technology. Dr. Conklin has undergraduate and graduate training in electrical/computer engineering and a master’s degree in management. He has been on the faculty of four medical schools, published over 100 scientific papers and edited four books. One of the textbooks, Imaging Techniques in Biology and Medicine published by Academic Press in 1987 provided the technical foundation for Bio-Imaging Technologies, Inc.
He is an Adjunct Professor of Radiology at Temple University School of Medicine. Early in his career Dr. Conklin flew Phantom fighter aircraft in the US Air Force.
David is the Senior Vice President of Client Services for ICON Medical Imaging.
During his more than twenty-five year career in the life sciences and medical imaging industries, his experience includes approximately 15 years of hands-on clinical imaging experience within hospital X-ray, CT, MR, US, NM, Cardiac Catheterization and Interventional imaging departments and approximately ten years of supporting medical imaging endpoints in clinical research trials. This broad base of experience provides Mr. La Point with valuable global business and industry perspectives.
In this role Dr. Martin is responsible for the overall management and operation of ICON Medical Imaging’s European office. Dr. Martin joined ICON Medical Imaging in January 2009 as the Senior Director, Business Development Europe.
Prior to joining ICON Medical Imaging, Dr. Martin has worked with leading CROs both full service and imaging core laboratories, with responsibilities of global sales, account management, management of the business development team and sales related functions. In these roles, Dr. Martin has built and held excellent relationships with existing and new accounts, including Roche, Novartis and Bayer.
Earlier in her career, Dr. Martin was Sales Manager and Technical Specialist at Baxter Oncology, Cellular Therapy. She initiated, and was scientifically and practically involved in trials for stem cell therapy in cardio-vascular diseases, for organ repair approaches and studies for tumor vaccination therapies using dendritic cells.
Dr. Martin was awarded her Ph.D. in Human Biology from Philipps University Marburg through her work on establishing new prognostic and predictive factors for breast cancer patients. Dr. Martin is an X-Ray Technician by training and before taking up her University education she worked 3 years in neuroradiology.
David has 15 years of experience as a research statistician in the pharmaceutical industry from Discovery statistical analysis through Phase 3 Clinical Trials.
As Project Statistician, he brings a great deal of knowledge and experience in the study design and analysis of imaging biomarkers and reader performance for all modalities. His experience includes statistical support for translational imaging, (preclinical to clinical), imaging methodology validation (Freesurfer, FDG-PET Lymphoma and MRI Liver Steatosis) and model development for Alzheimer’s Disease (advancing Bateman’s Method). Additionally, he is a co-inventor for the patent on Pixel Compounding method of ultrasound superresolution. While at Pfizer Central Research David served as Director of Neuroscience Research Statistics and is a core statistical team member of the Coalition Against Major Diseases – AD, Predictive Safety Testing Consortium and was the co-chair of the Biomarker Qualification Statistical Experts Team. He presently serves as a core team statistician on QIBA and UPICT-AD and has been the principle statistician or statistical team member for three different submissions to the FDA/BQRT process.
Prior to his role as a biostatistician, he worked as a research statistician for the U.S. Coast Guard and U.S. Navy.
David received a bachelor’s degree in Physics from the U.S. Naval Academy and a masters degree in Computational Biology from Rensselaer Polytechnic Institute. He obtained his Ph.D. at the University of Connecticut with his dissertation research in ultrasound multivariate statistical tumor tissue characterisation.